With new update in hand, Intellia CEO now claims one-time HAE gene editing treatment 'may be a functional cure'
In September, Intellia gave a first look into its one-time treatment for hereditary angioedema — a disease that causes severe swelling attacks — that directly edits the gene underlying the protein responsible for the attacks. It reported results on three patients: Two of the three were attack-free, and a third was attack-free after 10 weeks.
At the time, Intellia president and CEO John Leonard said he was “strongly encouraged” by the data readout. But with the latest cut of data, presented at an ACAAI meeting on Saturday, Leonard is ready to make a bolder claim — that the treatment “may be a functional cure,” he told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.